AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
How an Israeli engineer went from Rafael to iPhone Portrait Mode and a $300 million OpenAI exit
2
The man who helped build Palo Alto’s Cortex is leaving the company
3
“Our next milestone will be a billion-dollar valuation”: MIND triples valuation to $300 million with $72 million Series B
4
Five months old, Noetive raises $41 million Seed to build AI for the physical economy
5
Ondas in advanced talks to acquire Israeli defense company Nirosta Zafon for $250 million
More news

Stock

8 stories about Stock
מודיעין צה"ל מיחשוב 8200

CTech’s Daily Israeli Tech News Roundup

04.01.18|CTech
Israeli regulator proposes to ban crypto-focused companies from stock exchange. Israeli military unveils intelligence fusion unit. The shekel is getting stronger.
מנכ"ל טבע החדש קור שולץ 2

As U.S. Domestic Issuer, Teva Reveals Top Stock Owners

03.01.18|Dror Reich
Kåre Schultz, the newly-appointed CEO of generic drugmaker Teva Pharmaceutical Industries Ltd., is one of Teva's largest shareholders, a Wednesday filing to the U.S. Securities and Exchange Commission revealed
ד"ר אמיר ולדמן מייסדי הום סקינוביישנס מעורב בפרשת מובילאיי

Emails in Mobileye Insider Trading Case Pinpoint Leak’s Source

18.12.17|Tomer Ganon and Ran Abramson
The documents show how defendants communicated information about the stock’s expected spike
ד"ר אמיר ולדמן מייסדי הום סקינוביישנס מעורב בפרשת מובילאיי

Israeli Defendant Denies Mobileye Insider Trading Charges

08.12.17|Tomer Ganon and Ran Abramson
Amir Waldman, former vice president of Israel-based medical device company Syneron Medical, is being accused by the SEC of making over $4 million from insider trading in Mobileye securities
default image

Allergan to Sell Teva Shares to J.P. Morgan

14.11.17|Dror Reich and Lilach Baumer
Allergan announced it pledged its 9.8% stake in Teva to J.P. Morgan as collateral, as part of a loan agreement. The company already agreed to sell a quarter of the stock in the first quarter of 2018
אננס אננסים

MediWound Loses Stock Purchase Agreement Case

14.11.17|Dror Reich
The burn and wound treatment company was ordered to follow through on previous agreement to buy shares of biotech company Polyheal
מטה טבע פתח תקווה

Allergan Planning Sale of its Teva Stock

01.11.17|Dror Reich and Lilach Baumer
For the third quarter of 2017, Allergan reported an operating loss of $4.02 billion, $1.3 billion of which is due to the depreciation of its Teva securities.
מטה טבע פתח תקווה

Teva Offloads Holdings in Australia’s Mesoblast

25.10.17|Dror Reich and Lilach Baumer
The stem-cell therapy company diluted Teva’s shares through a new offering in August
Previous Articles